Professor Richard Lock is an acknowledged authority in the field of leukaemia. His work has not only resulted in the most clinically relevant experimental model to investigate paediatric acute lymphoblastic leukaemia, he was also the first to draw a direct link between anti-cancer drug-induced cell cycle arrest and their effects on proteins that directly regulate the cell cycle – opening up a new field of anti-cancer drug research.
His frequently world-first research achievements are matched by his profile both nationally and internationally, evidenced by his exceptional level of peer funding and many invitations to speak at leading symposia.